Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey

Documenti analoghi

• Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis
  di: Antonio Pisani, et al.
  Pubblicazione: (2024)
• A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies
  di: Myrl Holida, et al.
  Pubblicazione: (2024)
• Sodium‐glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real‐world case series
  di: Anthea Tsatsaronis, et al.
  Pubblicazione: (2024)
• Fabry‐specific treatment in Australia: time to align eligibility criteria with international best practices
  di: Kathleen Nicholls, et al.
  Pubblicazione: (2024)
• Female Patients With Mucopolysaccharidosis II ( MPS II ): Insights From the Hunter Outcome Survey
  di: Barbara K. Burton, et al.
  Pubblicazione: (2025)